Discover
Tecentriq (atezolizumab) / RocheBrazil issues new indication nod for Roche’s Tecentriq in triple-negative breast cancer (GBI Health) - Jul 11, 2019 - "Brazil’s National Health Surveillance Agency (ANVISA) recently issued a new indication approval for Swiss major Roche’s programmed death-ligand 1 (PD-L1) immunotherapy Tecentriq (atezolizumab). The approved indication is for use in triple-negative breast cancer (TNBC), and adds to earlier approvals for urothelial carcinoma (UC) and non-small cell lung cancer (NSCLC) issued in October 2017, as reported by GBI."Ibrance (palbociclib) / PfizerNew treatment approved for patients with breast cancer in Scotland (The Scotsman) - Jul 8, 2019 - "A new drug for patients with advanced breast cancer has been approved for use by the NHS in Scotland. The Scottish Medicines Consortium (SMC) said palbociclib (Ibrance) can increase the time before the condition progresses and delay the need for chemotherapy."Ibrance (palbociclib) / PfizerIbrance pricing: Wholesale acquisition cost of $11,856.54/package (Cantor Fitzgerald) - Jul 13, 2019 - A subscription to Thomson ONE is required to gain full access to report 67546938; Page no: 83; REPORT TITLE: "Don't hibernate this summer; Take the good with the bad into 2H19”; AUTHOR: Research Department; DATE: 06/27/2019Halaven (eribulin mesylate) / EisaiEribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Jul 8, 2019 - P2; N=118; Completed; Sponsor: Asan Medical Center; Active, not recruiting --> Completed; Trial completion date: Dec 2019 --> Jun 2019Tecentriq (atezolizumab) / RocheTecentriq sales projection: $3-12B (analyst projection: $5B) peak (Trefis) - Jul 10, 2019 - A subscription to Thomson ONE is required to gain full access to report 67553223; Page no: 5; REPORT TITLE: "Roche Holding Ltd- Trefis report: Roche Holdings - $37.70 Trefis price estimate”; AUTHOR: Research Department, et al; DATE: 06/30/2019Keytruda (pembrolizumab) / Merck (MSD)Keytruda sales projection: $10B+ peak (Trefis) - Jul 13, 2019 - A subscription to Thomson ONE is required to gain full access to report 67553248; Page no: 9; REPORT TITLE: "Merck & Co., Inc. Trefis report: Merck - $88.45 Trefis price estimate”; AUTHOR: Research Department; DATE: 07/01/2019Tecentriq (atezolizumab) / RocheTecentriq sales projection: >$2B by 2021 (Trefis) - Jul 10, 2019 - A subscription to Thomson ONE is required to gain full access to report 67545638; Page no: 2; REPORT TITLE: "Roche Holding Ltd- Can Roche's #1 therapeutic area with $28 billion in revenue grow further?”; AUTHOR: Research Department, et al; DATE: 06/27/2019Imfinzi (durvalumab) / AstraZeneca, CelgeneImfinzi WW sales projection: $3.7B+ (consensus: $3.8B) in 2024 (Guggenheim) - Jul 13, 2019 - A subscription to Thomson ONE is required to gain full access to report 67545132; Page no: 1; REPORT TITLE: "AZN.LN - Imfinzi sailing into new waters with positive CASPIAN results”; AUTHOR: Fernandez, Seamus, et al; DATE: 06/27/2019Piqray (alpelisib) / NovartisNCCN updates clinical practice guideline for breast cancer (Journal of Clinical Pathways) - Jul 9, 2019 - "The National Comprehensive Cancer Network (NCCN) updated their Clinical Practice Guideline for the treatment of breast cancer. In the workup for recurrent stage IV (M1) disease, an option was added to assess for PIK3CA mutation with tumor or liquid biopsy if the tumor is HR-positive and HER2-negative and if considering therapy with alpelisib...In the section for systemic therapy for ER-negative and/or PR-positive recurrent or stage IV (M1) disease, fulvestrant plus alpelisib was added as a category 1 option for PIK3CA-mutated tumors."Kisqali (ribociclib) / NovartisAn Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.(clinicaltrials.gov) - Jul 8, 2019 - P1/2; N=26; Active, not recruiting; Sponsor: Dana-Farber Cancer Institute; Recruiting --> Active, not recruiting; N=86 --> 26
